- Home
- HPAI vs MNPR Comparison
HPAI vs MNPR Comparison
Compare HPAI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPAI
- MNPR
- Stock Information
- Founded
- HPAI 2023
- MNPR 2014
- Country
- HPAI Singapore
- MNPR United States
- Employees
- HPAI N/A
- MNPR N/A
- Industry
- HPAI
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- HPAI
- MNPR Health Care
- Exchange
- HPAI NYSE
- MNPR Nasdaq
- Market Cap
- HPAI 221.3M
- MNPR 250.0M
- IPO Year
- HPAI N/A
- MNPR 2019
- Fundamental
- Price
- HPAI $6.40
- MNPR $40.25
- Analyst Decision
- HPAI
- MNPR Strong Buy
- Analyst Count
- HPAI 0
- MNPR 4
- Target Price
- HPAI N/A
- MNPR $43.00
- AVG Volume (30 Days)
- HPAI 4.8K
- MNPR 71.2K
- Earning Date
- HPAI 03-04-2025
- MNPR 03-27-2025
- Dividend Yield
- HPAI N/A
- MNPR N/A
- EPS Growth
- HPAI N/A
- MNPR N/A
- EPS
- HPAI N/A
- MNPR N/A
- Revenue
- HPAI $29,575,625.00
- MNPR N/A
- Revenue This Year
- HPAI N/A
- MNPR N/A
- Revenue Next Year
- HPAI N/A
- MNPR N/A
- P/E Ratio
- HPAI $32.25
- MNPR N/A
- Revenue Growth
- HPAI 132.36
- MNPR N/A
- 52 Week Low
- HPAI $3.07
- MNPR $1.72
- 52 Week High
- HPAI $14.74
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- HPAI N/A
- MNPR 49.34
- Support Level
- HPAI N/A
- MNPR $38.80
- Resistance Level
- HPAI N/A
- MNPR $45.60
- Average True Range (ATR)
- HPAI 0.00
- MNPR 5.19
- MACD
- HPAI 0.00
- MNPR -1.50
- Stochastic Oscillator
- HPAI 0.00
- MNPR 9.37
About HPAI HELPORT AI LTD
Helport AI Ltd is a AI technology company based in Singapore dedicated to serving enterprises' customer contact centers with intelligent products, solutions, and a digital platform. Its software, Helport AI Assist (AI Assist), provides tailored AI-powered guidance and oversight for contact center interactions and customer experience, with functions including Agent Assistant, Quality Assurance (QA) Assistant, Supervisor Assistant, and Knowledge Base Assistant.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.